Workshop B – Advancing Discovery of Novel Protein Targets Upstream of the Hippo Pathway
Time: 12:00 pm
day: Pre-Conference Workshop Day
Emerging literature has demonstrated the ability to target numerous proteins within the Hippo pathway and as evidence toward successful targeting of the pathway for therapeutic intervention grows, it is essential that we evaluate and optimize our ability to identify and drug novel protein targets within Hippo to capitalize on this ‘soon to be’ druggable pathway. The Hippo pathway is inhibited by cytoskeletal tension, i.e., mechano-transduction, which contributes to driving human malignancies and is defined by its dependence on Rho-ROCK signaling. In this workshop, we will discuss mechanisms by which mechano-transduction is modulated from the perspective of p190A RhoGAP (p190A), a pivotal negative regulator of Rho proteins. Indeed, p190A is encoded by ARHGAP35, which has emerged as a significantly altered gene in human cancer.
Attend this workshop to:
- Elucidate the role of mechano-transduction in Hippo signaling
- Understand mechanisms whereby ARHGAP35 alterations promote oncogenic cell transformation
- Identify novel signaling circuitries in cancer for which YAP/TAZ-TEAD inhibition represents a promising avenue for intervention